The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 1: Modifications to the androgen receptor

BJU International

Volumn 95, Issue 9, 2005, Pages 1320-1326

  Edwards, Joanne ^a   Bartlett, John M S ^a  

^a University Department of Surgery   (United Kingdom)

Author keywords

Androgen receptor; Hormone resistance; MAP kinase; PI3K and PKC

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; ANTIANDROGEN; GONADORELIN AGONIST; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE C; TESTOSTERONE;

GENE AMPLIFICATION; HORMONE RESISTANCE; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RECEPTOR INTRINSIC ACTIVITY; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS, HORMONAL; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TESTOSTERONE;

EID: 20444403792     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2005.05526.x     Document Type: Review

References (34)

1. Schulz WA, Burchardt M, Cronauer MV. Molecular biology of prostate cancer. Mol Human Reprod 2003; 9: 437-48
2. Trachtenberg J, Blackledge G. Looking to the future. Advances in the management of hormone-refractory prostate cancer. Eur Urol Suppl 2002; 1: 44-53
3. Sciarra A, Cardi A, Di Silverio F. Antiandrogen monotherapy. Recommendations for the treatment of prostate cancer. Urologia Intis 2004; 72: 91-8
4. Suzuki H, Ueda T, Ichikawa T, Ito H. Androgen receptor involvement in the progression of prostate cancer. Endocrine-Related Cancer 2003; 10: 209-16
5. Lee HJ, Chang C. Recent advances in androgen receptor action. Cellular Mol Life Sci 2003; 60: 1613-22
6. Zhu Z, Becklin RR, Desiderio DM, Dalton JT. Identification of a novel phosphorylation site in human androgen receptor by mass spectrometry. Biochem Biophys Res Comms 2001 ; 284: 836-44
7. Chang C, Saltzman A, Yeh S et al. Androgen receptor: an overview. Crit Rev Eukaryotic Gene Expression 1995; 5: 97-125
8. Culig Z, Hobisch A, Bartsch G, Klocker H. Expression and function of androgen receptor in carcinoma of the prostate. Microscopy Res Technique 2000; 51: 447-55
9. Culig Z, Hobisch A, Hittmair A et al. Expression, structure, and function of androgen receptor in advanced prostatic carcinoma. Prostate 1998; 35: 63-70
10. Taplin ME, Rajeshkumar B, Halabi S et al. Androgen receptor mutations in androgen-in dependent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol 2003; 21: 2673-8
11. Taplin ME, Bubley GJ, Ko YJ et al. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 1999; 59: 2511-5
12. Thompson J, Hyytinen ER, Haapala K et al. Androgen receptor mutations in high-grade prostate cancer before hormonal therapy. Laboratory Invest 2003; 83: 1709-13
13. Buchanan G, Greenberg NM, Scher HI et al. Co-location of androgen receptor gene mutations in prostate cancer. Clin Cancer Res 2001; 7: 1273-81
14. Wallen MJ, Linja M, Kaartinen K, Schleutker J, Visakorpi T. Androgen receptor gene mutations in hormone-refractory prostate cancer. J Pathol 1999; 189: 559-63
15. Patel BJ, Pantuck AJ, Zisman A et al. CL1-GFP. an androgen independent metastatic tumor model for prostate cancer. J Urol 2000; 164: 1420-5
16. Thakkar H, Chen XF, Tyan F et al. Pro-survival function of Akt/protein kinase B in prostate cancer cells. Relationship with TRAIL resistance. J Biol Chem 2002; 277: 30408
17. Marcelli M, Ittmann M, Mariani S et al. Androgen receptor mutations in prostate cancer. Cancer Res 2000; 60: 944-9
18. Koivisto PA, Helin HJ. Androgen receptor gene amplification increases tissue PSA protein expression in hormone-refractory prostate carcinoma. J Pathol 1999; 189: 219-23
19. Edwards J, Krishna NS, Bartlett JMS. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer 2003; 89: 552-6
20. Chen CD, Welsbie DS, Tran C et al. Molecular determinants of resistance to antiandrogen therapy. Nature Med 2004; 10: 33-9
21. Blok LJ, de Ruiter PE, Brinkmann AO. Forskolin-induced dephosphorylation of the androgen receptor impairs ligand binding. Biochemistry 1998; 37: 3850-7
22. Rochette-Egly C. Nuclear receptors. Integration of multiple signalling pathways through phosphorylation. Cellular Signalling 2003; 15: 355-66
23. Lin HK, Yeh SY, Kang HY, Chang CS. Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. Proc Natl Acad Sci USA 2001; 98: 7200-5
24. Uzgare AR, Kaplan PJ, Greenberg NM. Differential expression and/or activation of P38MAPK, Erk1/2, and Jnk during the initiation and progression of prostate cancer. Prostate 2003; 55: 128-39
25. Bakin RE, Gioeli D, Sikes RA, Bissonette EA, Weber MJ. Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res 2003; 63: 1981-9
26. Lin HK, Hu YC, Yang L et al. Suppression versus induction of androgen receptor functions by the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer LNCaP cells with different passage numbers. J Biol Chem 2003; 278: 50902-7
27. Liao YD, Grobholz R, Abel U et al. Increase of AKT/PKB expression correlates with Gleason pattern in human prostate cancer. Int J Cancer 2003; 107: 676-80
28. Ghosh PM, Malik S, Bedolla R, Kreisberg JI. Akt in prostate cancer: Possible role in androgen-independence. Current Drug Metabolism 2003; 4: 487-96
29. Gao N, Zhang Z, Jiang BH, Shi XL. Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer. Biochem Biophys Res Comms 2003; 310: 1124-32
30. Murillo H, Huang HJ, Schmidt U, Smith DI, Tindall DJ. Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. Endocrinology 2001; 142: 4795-805
31. Davies MA, Koul D, Dhesi H et al. Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN. Cancer Res 1999; 59: 2551-6
32. Malik SN, Brattain M, Ghosh PM et al. Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res 2002; 8: 1168-71
33. Iahn M, Sundel K, Gleave M et al. Protein kinase C-alpha in prostate cancer. BJU Int 2004; 93: 1076-81
34. Gioeli D, Ficarro SB, Kwiek JJ et al. Androgen receptor phosphorylation - Regulation and identification of the phosphorylation sites. J Biol Chem 2002; 277: 29304-14